Related Experiment Video
Updated: May 20, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Guidelines for the quality control of population pharmacokinetic-pharmacodynamic analyses: an industry perspective
P L Bonate1, A Strougo, A Desai
1Astellas Pharma Global Development, 1 Astellas Way, Northbrook, IL 60062, USA. peter.bonate@us.astellas.com
Abstract:
Quality population modeling and simulation analyses and reports are something every modeler desires. However, little attention in the literature has been paid to what constitutes quality regarding population analyses. Very rarely do published manuscripts contain any statement about quality assurance of the modeling results contained therein. The purpose of this manuscript is to present guidelines for the quality assurance of population analyses, particularly with regards to the use of NONMEM from an industrial perspective. Quality guidelines are developed for the NONMEM installation itself, NONMEM data sets, control streams, output listings, output data files and resultant post-processing, reporting of results, and the review processes. These guidelines were developed to be thorough yet practical, though are not meant to be completely comprehensive. It is our desire to ensure that what is reported accurately reflects the collected data, the modeling process, and model outputs for a modeling project.
Related Concept Videos
Analysis of Population Pharmacokinetic Data
Dosage Regimens: Partial Pharmacokinetic Parameters
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Model Approaches for Pharmacokinetic Data: Physiological Models
Pharmacodynamic Models: Overview

